<DOC>
	<DOCNO>NCT01572545</DOCNO>
	<brief_summary>The primary aim study comparative effect zolendronic acid versus denosumab serum sclerostin level postmenopausal woman low bone mass . Secondary aim comparative effect serum dickkopf-1 , osteoprotegerin , receptor activator nuclear factor kappaB ligand ( RANKL ) bone turnover marker ( procollagen type I N-terminal peptide [ PINP ] C-terminal cross-linking telopeptide type I collagen [ CTX ] ) .</brief_summary>
	<brief_title>Comparative Effect Zoledronic Acid Versus Denosumab Serum Sclerostin Postmenopausal Women With Low Bone Mass</brief_title>
	<detailed_description>Osteoporosis common bone disease , cause relatively increased rate bone resorption osteoclasts exceeds rate bone formation osteoblast , result net loss bone mass . To-date , antiresorptive agent , inhibit osteoclast activity induce apoptosis , consider cornerstone osteoporosis prevention treatment . Bisphosphonates currently represent first line antiresorptive agent management postmenopausal osteoporosis . Zoledronic acid consider to-date potent bisphosphonate . A once-yearly infusion intravenous zoledronic acid decrease bone turnover , improve bone density decrease vertebral non-vertebral fracture risk . Most recently , denosumab ( AMG-162 ) launch treatment postmenopausal osteoporosis . Denosumab , fully human monoclonal IgG2 antibody human RANKL , specifically bind neutralizes receptor activator nuclear factor kappaB ligand ( RANKL ) order decrease bone resorption subsequent bone loss . Subcutaneous administration denosumab every six month decrease bone turnover marker , increase bone mineral density reduce vertebral non-vertebral fracture risk . The role sclerostin bone metabolism emerge . Sclerostin secrete expression SOST gene . In adult human bone , sclerostin express osteocytes inhibits bone formation osteoblast . It propose sclerostin expression newly embed osteocytes onset osteoid mineralization may serve negative feedback signal osteoblast prevent overfill basic multicellular unit . Although zoledronic acid denosumab currently regard potent antiresorptive agent , head-to-head comparative study . This study primarily aim comparative effect zoledronic acid denosumab serum sclerostin level secondarily serum dickkopf-1 , osteoprotegerin , RANKL bone turnover marker ( procollagen type I N-terminal peptide [ PINP ] C-terminal cross-linking telopeptide type I collagen [ CTX ] ) .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Caucasian postmenopausal woman older 40 year Low bone mass lumbar spine ( L2L4 ) femoral neck ( BMD Tscore â‰¤ 2.0 ) BMD Tscore &gt; 2.0 coexistent lowenergy fracture vertebral , femoral neck forearm Patient 's informed consent participate Secondary osteoporosis Any bone mineral disorder osteoporosis , include primary secondary hyperparathyroidism , Paget 's disease bone , osteogenesis imperfecta , rheumatologic disease , paraplegia , chronic immobilization Severe liver kidney disease ( creatinine clearance &lt; 60ml/min/1.73m2 ) liver kidney transplantation Premature ovarian failure Uncontrolled thyroid disease Any malignancy Any musculoskeletal injury surgical procedure 6 month prior baseline Dental surgery teeth remove 3 month prior baseline plan History concomitant medication could affect bone metabolism , include immunosuppressive , anticonvulsant , antiviral antituberculosis agent , addictive drug , corticosteroid , nonsteroidal antiinflammatory drug , amiodarone , thiazolidinediones , interferon , metronidazole , tamoxifen</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>bone turnover</keyword>
	<keyword>denosumab</keyword>
	<keyword>postmenopausal osteoporosis</keyword>
	<keyword>sclerostin</keyword>
	<keyword>zolendronic acid</keyword>
</DOC>